In colorectal cancer (CRC), PIK3CA mutations have been shown to reprogram glutamine metabolism by upregulating glutamate pyruvate transaminase 2 (GPT2), thereby increasing tumor cell dependence on glutamine. Here, PIK3CA is linked to neoplasm.